{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:29:06Z","timestamp":1767180546610,"version":"build-2238731810"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The entry and infectivity of a virus are determined by its interaction with the host. SARS-CoV-2, the virus responsible for COVID-19, utilizes the spike (S) protein to attach to and enter host cells. Recent studies have identified neuropilin-1 (NRP1) as a crucial facilitator for the entry of SARS-CoV-2. The binding of the spike protein to the b1 domain of NRP1 has been shown to enhance viral infection twofold. Consequently, targeting NRP1 to disrupt this interaction represents a promising strategy to mitigate viral infection. In this study, a small molecule library of approximately 10,000 compounds was screened to identify those that could inhibit the interaction between NRP1 and the spike protein by targeting the b1 domain of NRP1. The crystallographic structure of the b1 domain of human NRP1 (PDB entry: 7JJC) was used for this purpose. Following virtual screening, docking studies, and evaluation of binding affinity and ADMET properties, 10 compounds were shortlisted. The top two candidates, AZD3839 and LY2090314, were selected for molecular dynamics simulation studies over 100 ns to assess binding stability. MM\/GBSA calculations indicated that both AZD3839 and LY2090314 exhibited strong and stable binding to the b1 domain of NRP1. Computational modeling of the interaction between the b1 domain of NRP1 and the receptor-binding domain of the spike protein suggested that AZD3839 and LY2090314 could effectively hinder the NRP1-spike interaction. Therefore, these compounds may serve as potential drug candidates to reduce SARS-CoV-2 infectivity.<\/jats:p>","DOI":"10.1371\/journal.pone.0310855","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:28:22Z","timestamp":1738762102000},"page":"e0310855","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Insilico targeting of virus entry facilitator NRP1 to block SARS-CoV2 entry"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8399-0932","authenticated-orcid":true,"given":"Nousheen","family":"Bibi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maleeha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahzad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Shahzad","family":"Chohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-0565","authenticated-orcid":true,"given":"Mohammad Amjad","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"pone.0310855.ref001","first-page":"143","article-title":"Neuropilin 1: A Novel Entry Factor for SARS-CoV-2 Infection and a Potential Therapeutic Target","volume":"15","author":"E Chekol Abebe","year":"2021","journal-title":"Biologics"},{"key":"pone.0310855.ref002","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.2147\/IDR.S268033","article-title":"Awareness of Health Professionals on COVID-19 and Factors Affecting It Before and During Index Case in North Shoa Zone, Ethiopia","volume":"13","author":"A Abebe","year":"2020","journal-title":"Infect Drug Resist"},{"key":"pone.0310855.ref003","first-page":"109","article-title":"The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China","volume":"2020","author":"Y Yang","journal-title":"J Autoimmun"},{"issue":"4","key":"pone.0310855.ref004","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"G Li","year":"2020","journal-title":"J Med Virol"},{"issue":"4","key":"pone.0310855.ref005","article-title":"Virology, epidemiology, pathogenesis, and control of COVID-19","volume":"12","author":"Y Jin","year":"2020","journal-title":"Viruses"},{"issue":"6518","key":"pone.0310855.ref006","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"L Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"issue":"6494","key":"pone.0310855.ref007","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.abb7015","article-title":"Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2","volume":"368","author":"J Shi","year":"2020","journal-title":"Science"},{"issue":"7798","key":"pone.0310855.ref008","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"P Zhou","year":"2020","journal-title":"Nature"},{"issue":"7809","key":"pone.0310855.ref009","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"R W\u00f6lfel","year":"2020","journal-title":"Nature"},{"issue":"4","key":"pone.0310855.ref010","first-page":"593","article-title":"Recent insights into the neuropilin-1 role in SARS-CoV-2 infection","volume":"41","author":"JL Vique-S\u00e1nchez","year":"2021","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"pone.0310855.ref011","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"M Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"6503","key":"pone.0310855.ref012","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1126\/science.abc6156","article-title":"How does SARS-CoV-2 cause COVID-19?","volume":"369","author":"NJ Matheson","year":"2020","journal-title":"Science"},{"issue":"6518","key":"pone.0310855.ref013","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"L Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"issue":"7","key":"pone.0310855.ref014","first-page":"361","article-title":"Autophagy, a targeted therapy for SARS-CoV-2?","volume":"20","author":"AM Cuervo","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"pone.0310855.ref015","first-page":"253","article-title":"Enhancing the effects of COVID-19 through viral evolution","volume":"18","author":"M. Kielian","year":"2020","journal-title":"Nat Rev Microbiol"},{"issue":"11","key":"pone.0310855.ref016","first-page":"2431","article-title":"SARS-CoV-2 neuropilin-1 binding peptide blocks virus entry and loss of pain","volume":"162","author":"A Moutal","year":"2021","journal-title":"Pain"},{"issue":"7","key":"pone.0310855.ref017","first-page":"361","article-title":"Autophagy, a targeted therapy for SARS-CoV-2?","volume":"20","author":"AM Cuervo","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"6518","key":"pone.0310855.ref018","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1126\/science.abd3072","article-title":"Neuropilin-1 is a host factor for SARS-CoV-2 infection","volume":"370","author":"JL Daly","year":"2020","journal-title":"Science"},{"issue":"4","key":"pone.0310855.ref019","first-page":"593","article-title":"Recent insights into the neuropilin-1 role in SARS-CoV-2 infection","volume":"41","author":"JL Vique-S\u00e1nchez","year":"2021","journal-title":"Cell Mol Neurobiol"},{"key":"pone.0310855.ref020","article-title":"Post-translational regulation of neuropilin-1 expression by the proteasome inhibitor bortezomib","volume":"80","author":"T Tezuka","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"pone.0310855.ref021","article-title":"Neuropilin-1 as a biomarker for SARS-CoV-2 infection","volume":"22","author":"J Davies","year":"2020","journal-title":"Mol Med Rep"},{"issue":"15","key":"pone.0310855.ref022","first-page":"1721","article-title":"Pharmacological potential of neuropilin-1 in treatment of human diseases: Current status and future perspectives","volume":"18","author":"S Roy","year":"2017","journal-title":"Curr Drug Targets"},{"issue":"46","key":"pone.0310855.ref023","first-page":"29120","article-title":"Neuropilin functions as an essential cell surface receptor","volume":"290","author":"HF Guo","year":"2015","journal-title":"J Biol Chem"},{"issue":"4","key":"pone.0310855.ref024","first-page":"517","article-title":"Neuropilin-1: A multifunctional neural receptor protein","volume":"132","author":"F Nakamura","year":"2002","journal-title":"J Biochem"},{"key":"pone.0310855.ref025","first-page":"409","article-title":"Mapping of vascular ZIP codes by phage display","volume":"460","author":"T Teesalu","year":"2009","journal-title":"Methods Enzymol"},{"issue":"1","key":"pone.0310855.ref026","doi-asserted-by":"crossref","first-page":"e1009153","DOI":"10.1371\/journal.ppat.1009153","article-title":"The role of neuropilin-1 in COVID-19","volume":"17","author":"BS Mayi","year":"2021","journal-title":"PLoS Pathog"},{"issue":"3","key":"pone.0310855.ref027","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.str.2005.01.006","article-title":"Software extensions to UCSF Chimera for interactive visualization of large molecular assemblies","volume":"13","author":"TD Goddard","year":"2005","journal-title":"Structure"},{"key":"pone.0310855.ref028","first-page":"74","article-title":"Neuropilin-1 as a marker of SARS-CoV-2 entry and infectivity","volume":"465","author":"C Cantin","year":"2019","journal-title":"J Immunol Methods"},{"issue":"16","key":"pone.0310855.ref029","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: Fast, flexible, and free","volume":"26","author":"D Van Der Spoel","year":"2005","journal-title":"J Comput Chem"},{"issue":"Pt 8","key":"pone.0310855.ref030","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1107\/S0907444904011679","article-title":"PRODRG: A tool for high-throughput crystallography of protein-ligand complexes","volume":"60","author":"AW Sch\u00fcttelkopf","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"7","key":"pone.0310855.ref031","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00249-011-0700-9","article-title":"Definition and testing of the GROMOS force-field versions 54A7 and 54B7","volume":"40","author":"N Schmid","year":"2011","journal-title":"Eur Biophys J"},{"issue":"19","key":"pone.0310855.ref032","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A smooth particle mesh Ewald method","volume":"103","author":"U Essmann","year":"1995","journal-title":"J Chem Phys"},{"issue":"4","key":"pone.0310855.ref033","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nprot.2010.5","article-title":"I-TASSER: A unified platform for automated protein structure and function prediction","volume":"5","author":"A Roy","year":"2010","journal-title":"Nat Protoc"},{"issue":"3","key":"pone.0310855.ref034","first-page":"123","article-title":"Overview on current COVID-19 pandemic and its impact on public health","volume":"8","author":"J Iqbal","year":"2014","journal-title":"J Clin Exp Res"},{"issue":"6483","key":"pone.0310855.ref035","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"D Wrapp","journal-title":"Science"},{"issue":"5","key":"pone.0310855.ref036","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1021\/jm901755g","article-title":"Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction","volume":"53","author":"A Jarvis","year":"2010","journal-title":"J Med Chem"},{"issue":"9","key":"pone.0310855.ref037","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/acs.jmedchem.8b00210","article-title":"Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGF\u03b2) Production in Regulatory T-Cells","volume":"61","author":"J Powell","year":"2018","journal-title":"J Med Chem"},{"issue":"6518","key":"pone.0310855.ref038","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"L. Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"issue":"49","key":"pone.0310855.ref039","doi-asserted-by":"crossref","first-page":"41245","DOI":"10.1074\/jbc.M112.409110","article-title":"Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease","volume":"287","author":"F Jeppsson","year":"2012","journal-title":"J Biol Chem"},{"issue":"8","key":"pone.0310855.ref040","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/15384047.2019.1595283","article-title":"Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses","volume":"20","author":"I Sahin","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"pone.0310855.ref041","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2020.09.014","article-title":"Repurposing anticancer drugs for the management of COVID-19","volume":"141","author":"K El Bairi","year":"2020","journal-title":"Eur J Cancer"},{"issue":"23","key":"pone.0310855.ref042","doi-asserted-by":"crossref","first-page":"12812","DOI":"10.1080\/07391102.2021.1977698","article-title":"Drug repositioning against COVID-19: a first line treatment","volume":"40","author":"N Bibi","year":"2022","journal-title":"J Biomol Struct Dyn"},{"key":"pone.0310855.ref043","doi-asserted-by":"crossref","first-page":"116040","DOI":"10.1016\/j.bmc.2021.116040","article-title":"Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking","volume":"33","author":"JL Vique-S\u00e1nchez","year":"2021","journal-title":"Bioorg Med Chem"},{"issue":"8","key":"pone.0310855.ref044","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1021\/acschemneuro.0c00619","article-title":"Novel compounds targeting neuropilin receptor 1 with potential to interfere with SARS-CoV-2 virus entry","volume":"12","author":"S. Perez-Miller","year":"2021","journal-title":"ACS Chemical Neuroscience"},{"issue":"14","key":"pone.0310855.ref045","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1016\/j.bpj.2021.05.026","article-title":"Neuropilin-1 assists SARS-CoV-2 infection by stimulating the separation of Spike protein S1 and S2","volume":"120","author":"ZL Li","year":"2021","journal-title":"Biophys J"},{"issue":"1","key":"pone.0310855.ref046","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s12885-018-4474-7","article-title":"Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro","volume":"18","author":"S Kunnimalaiyaan","year":"2018","journal-title":"BMC Cancer"},{"issue":"6","key":"pone.0310855.ref047","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3390\/cells9061388","article-title":"Glycogen Synthase Kinase 3\u03b2 in Cancer Biology and Treatment","volume":"9","author":"T Domoto","year":"2020","journal-title":"Cells"},{"key":"pone.0310855.ref048","doi-asserted-by":"crossref","first-page":"100019","DOI":"10.1016\/j.crviro.2022.100019","article-title":"Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern","volume":"3","author":"L Murer","year":"2022","journal-title":"Curr Res Virol Sci"},{"issue":"13","key":"pone.0310855.ref049","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.3390\/jcm10132772","article-title":"The Role of Neuropilin-1 (NRP-1) in SARS-CoV-2 Infection: Review","volume":"10","author":"M Gudowska-Sawczuk","year":"2021","journal-title":"Journal of Clinical Medicine"},{"key":"pone.0310855.ref050","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10753-022-01734-w","article-title":"SARS-CoV-2 Variants Show a Gradual Declining Pathogenicity and Pro-Inflammatory Cytokine Stimulation, an Increasing Antigenic and Anti-Inflammatory Cytokine Induction, and Rising Structural Protein Instability: A Minimal Number Genome-Based Approach","volume":"46","author":"D. Barh","year":"2023","journal-title":"Inflammation"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0330614","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:28:45Z","timestamp":1738762125000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0310855"}},"subtitle":[],"editor":[{"given":"Pramodkumar Pyarelal","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0310855","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}